CICI
XBI icon

Capital Investment Counsel Inc’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Investment Counsel Inc’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.71M Sell
29,740
-1,050
-3% -$142K 0.51% 36
2026
Q1 		$3.93M Sell
30,790
-400
-1% -$49.9K 0.48% 36
2025
Q4 		$3.8M Hold
31,190
– – 0.45% 39
2025
Q3 		$3.13M Hold
31,190
– – 0.38% 45
2025
Q2 		$2.59M Buy
31,190
+30,985
+15,115% +$2.47M 0.34% 50
2025
Q1 		$16.6K Hold
205
– – ﹤0.01% 235
2024
Q4 		$18.5K Hold
205
– – ﹤0.01% 237
2024
Q3 		$20.3K Hold
205
– – ﹤0.01% 217
2024
Q2 		$19K Hold
205
– – ﹤0.01% 216
2024
Q1 		$19.5K Hold
205
– – ﹤0.01% 212
2023
Q4 		$18.3K Hold
205
– – ﹤0.01% 211
2023
Q3 		$15K Buy
+205
New +$16.4K ﹤0.01% 204
2020
Q3 		– Sell
-3,011
Closed -$337K – 189
2020
Q2 		$337K Sell
3,011
-1,625
-35% -$160K 0.13% 89
2020
Q1 		$359K Buy
4,636
+200
+5% +$17.7K 0.14% 94
2019
Q4 		$422K Sell
4,436
-25
-0.6% -$2.16K 0.14% 100
2019
Q3 		$340K Buy
4,461
+250
+6% +$20.8K 0.12% 106
2019
Q2 		$369K Buy
4,211
+150
+4% +$12.8K 0.13% 108
2019
Q1 		$368K Sell
4,061
-150
-4% -$12.8K 0.14% 108
2018
Q4 		$302K Hold
4,211
– – 0.13% 106
2018
Q3 		$404K Sell
4,211
-25
-0.6% -$2.42K 0.15% 96
2018
Q2 		$403K Buy
4,236
+200
+5% +$18.4K 0.16% 93
2018
Q1 		$354K Buy
4,036
+100
+3% +$9.13K 0.15% 100
2017
Q4 		$334K Sell
3,936
-300
-7% -$25.1K 0.14% 101
2017
Q3 		$367K Sell
4,236
-325
-7% -$26.1K 0.16% 100
2017
Q2 		$352K Sell
4,561
-225
-5% -$16K 0.16% 101
2017
Q1 		$332K Buy
4,786
+250
+6% +$16.8K 0.15% 104
2016
Q4 		$268K Buy
+4,536
New +$280K 0.13% 116

Other funds holding XBI

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
WT
Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

Capital Investment Counsel Inc's XBI Position: Q2 2026 in Review

Capital Investment Counsel Inc reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.4% in Q2 2026, selling an estimated $142K and leaving 29,740 shares worth $4.71M. The position accounts for 0.51% of the portfolio, ranked #36.

Capital Investment Counsel Inc first reported a position in XBI in Q4 2016 and has held it in 27 quarters since. 551 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Capital Investment Counsel Inc held 29,740 shares of State Street SPDR S&P Biotech ETF worth $4.71M as of Q2 2026.
  • Capital Investment Counsel Inc sold 1,050 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $142K.
  • State Street SPDR S&P Biotech ETF made up 0.51% of Capital Investment Counsel Inc's portfolio in Q2 2026, its #36 holding.
  • Capital Investment Counsel Inc first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 27 quarters since.
  • 551 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Capital Investment Counsel Inc's 13F filing for Q2 2026, filed 27 Jul 2026.